Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Times Cited: 305
Times Cited: 305
Times Cited
Times Co-cited
Similarity
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
70
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
48
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
45
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
37
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
36
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
35
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
C S Kovacs, V Seshiah, R Swallow, R Jones, H Rattunde, H J Woerle, U C Broedl. Diabetes Obes Metab 2014
C S Kovacs, V Seshiah, R Swallow, R Jones, H Rattunde, H J Woerle, U C Broedl. Diabetes Obes Metab 2014
32
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
30
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
30
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
30
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
28
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
J Rosenstock, A Jelaska, C Zeller, G Kim, U C Broedl, H J Woerle. Diabetes Obes Metab 2015
J Rosenstock, A Jelaska, C Zeller, G Kim, U C Broedl, H J Woerle. Diabetes Obes Metab 2015
25
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
25
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
24
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
24
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
24
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J Woerle, Uli C Broedl. Diabetes Care 2014
Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J Woerle, Uli C Broedl. Diabetes Care 2014
23
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
23
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
Clifford J Bailey, Jorge L Gross, Anne Pieters, Arnaud Bastien, James F List. Lancet 2010
22
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
30
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh. Diabetes Care 2014
20
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
22
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
20
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
J Rosenstock, L J Seman, A Jelaska, S Hantel, S Pinnetti, T Hach, H J Woerle. Diabetes Obes Metab 2013
J Rosenstock, L J Seman, A Jelaska, S Hantel, S Pinnetti, T Hach, H J Woerle. Diabetes Obes Metab 2013
19
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
19
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
19
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
20
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal. Diabetes Care 2015
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal. Diabetes Care 2015
18
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
18
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
18
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
K Strojek, K H Yoon, V Hruba, M Elze, A M Langkilde, S Parikh. Diabetes Obes Metab 2011
K Strojek, K H Yoon, V Hruba, M Elze, A M Langkilde, S Parikh. Diabetes Obes Metab 2011
18
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2015
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2015
23
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
Andrew Lewin, Ralph A DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
Andrew Lewin, Ralph A DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
17
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari, Nahoko Takahashi, Yutaka Susuta, Hideki Kuki. Expert Opin Pharmacother 2014
Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari, Nahoko Takahashi, Yutaka Susuta, Hideki Kuki. Expert Opin Pharmacother 2014
18
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
17
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali, James F List. Diabetes Care 2012
Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali, James F List. Diabetes Care 2012
17
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. J Am Geriatr Soc 2014
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh. J Am Geriatr Soc 2014
17
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
17
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle, Uli C Broedl. Clin Ther 2015
Christopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans-Juergen Woerle, Uli C Broedl. Clin Ther 2015
26
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
F Zaccardi, D R Webb, Z Z Htike, D Youssef, K Khunti, M J Davies. Diabetes Obes Metab 2016
F Zaccardi, D R Webb, Z Z Htike, D Youssef, K Khunti, M J Davies. Diabetes Obes Metab 2016
17
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
16
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
17
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
16
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Diabetes Care 2009
16
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
L Ji, P Han, Y Liu, G Yang, N K Dieu Van, U Vijapurkar, R Qiu, G Meininger. Diabetes Obes Metab 2015
L Ji, P Han, Y Liu, G Yang, N K Dieu Van, U Vijapurkar, R Qiu, G Meininger. Diabetes Obes Metab 2015
27
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
E Ferrannini, L Seman, E Seewaldt-Becker, S Hantel, S Pinnetti, H J Woerle. Diabetes Obes Metab 2013
E Ferrannini, L Seman, E Seewaldt-Becker, S Hantel, S Pinnetti, H J Woerle. Diabetes Obes Metab 2013
16
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
16
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
16
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
Donald E Kohan, Paola Fioretto, Weihua Tang, James F List. Kidney Int 2014
16
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
15
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.